Objectives: Genetically modified lactic acid bacteria may be a way to deliver vaccinal epitopes in the gastrointestinal tract.
Aim: Three strains of lactic acid bacteria were studied for their pharmacokinetics in the human gastrointestinal tract.
Methods: The survival of the strains was studied up to the ileum in six subjects each, after ingestion of 150 g of fermented milk. The strains and their concentrations in the products were Lactobacillus fermentum KLD (107 cfu/g), Lactobacillus plantarum NCIMB 8826 (108 cfu/g), and Lactococcus lactis MG 1363 (108 cfu/g). Ileal fluid was aspirated by intestinal intubation and immediately cultured. L. plantarum NCIMB 8826, which was found in high concentrations in the ileum, was studied for its survival in the faeces after consumption of 150 g of fermented milk three times daily for 7 days. Faecal samples were collected for culture.
Results: The concentration of L. plantarum NCIMB 8826 in the ileum reached 108 cfu/mL after a single dose, with a survival of 7%. L. fermentum KLD and Lc. lactis MG 1363 had lower (0.5 and 1.0%, respectively) and shorter (4 h) survival in the ileum. During the 7-day ingestion period, L. plantarum NCIMB 8826 reached high concentrations (108 cfu/g) in the faeces, with a survival of 25 +/- 29%. None of the strains colonized.
Conclusions: L. plantarum NCIMB 8826 has a promising pharmacokinetic profile as a candidate vaccine vehicle.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2036.2000.00763.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of NCIMB 30094 as a technological additive (functional group: silage additive) for use in fresh material for all animal species. The additive is intended for use at a proposed minimum concentration of 1 × 10 colony forming units (CFU)/kg fresh plant material. The bacterial species is considered by EFSA to be suitable for the qualified presumption of safety approach to safety assessment.
View Article and Find Full Text PDFFollowing a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of NCIMB 41028 as a technological additive to improve ensiling of fresh plant material. The additive is intended for use in all fresh material for all animal species at a proposed minimum concentration of 1 × 10 colony forming units (CFU)/kg fresh plant material. The bacterial species is considered by EFSA to be suitable for the qualified presumption of safety approach to safety assessment.
View Article and Find Full Text PDFFollowing a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of NCIMB 30148 as a technological additive to improve ensiling of fresh plant material. The additive is intended for use in all fresh material for all animal species at a proposed minimum concentration of 1 × 10 colony forming units (CFU)/kg fresh plant material. The bacterial species is considered by EFSA to be suitable for the qualified presumption of safety approach to safety assessment.
View Article and Find Full Text PDFFollowing a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of the authorisation of NCIMB 40027 as a technological additive (functional group: silage additives) for use in fresh material for all animal species. The applicant has provided evidence that the additive currently on the market complies with the existing terms of the authorisation. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) concluded that the additive remains safe for all animal species, consumers, and the environment.
View Article and Find Full Text PDFThe protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice.
PLoS One
October 2024
Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang, Hunan, People's Republic of China.
Article Synopsis
- * Probiotic lactobacillus strains, especially Lacticaseibacillus rhamnosus GG (LGG), show promise in enhancing immune responses to respiratory infections.
- * In a study with mice, LGG reduced M. pneumoniae infection severity, improved immune response, and lessened lung inflammation, suggesting it may be an effective treatment strategy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!